# DDLS 2026 — Week 4 interview transcript

**Lab:** Interview a Structural-Biology Data Owner
**Data owner:** Dr. Margit Holló — Structural cancer-biology researcher (p53)
**Student:** Baris Kara <baris51519@gmail.com>
**Exported:** 2026-09-16T12:03:00+00:00

> This is the record of your interview with the data owner. Hand it to your analyst agent as the raw source for `AGENTS.md` and `spec.md`.

---

**You**:

Can you walk me through the protein and what you are ultimately trying to decide from the AlphaFold model?

**Dr. Margit Holló**:

I’m Dr Margit Holló at Karolinska Institutet, working on human p53. The sequence contains the N-terminal regulatory region, the central DNA-binding core, and the C-terminal regulatory and tetramerisation regions; the AlphaFold model is the 3D picture of that protein. Ultimately, I want to know whether the model’s residue-by-residue scores are higher for the core, **94–312**, than for the N-terminal region, **1–93**, before treating the core as the better-supported region in our protocol. My medicinal-chemistry collaborator wants a defined target on the neat front-end helix, around **18–28**; which part will you examine first?

**You**:

What exactly is the molecule you are studying — one protein, multiple chains, or a complex? Roughly how many residues are there?

**Dr. Margit Holló**:

One protein: human p53, UniProt **P04637**, 393 amino acids. The model is the single polypeptide, not a p53–MDM2 complex or a multichain assembly. Are you checking the chain definition before calculating the two regional means?

**You**:

I would like to understand the project before I check something, so please bare with me and save your questions to later discussion. Do you have the exact sequence as a FASTA file?

**Dr. Margit Holló**:

Yes. **`p53.fasta`** contains the plain human p53 reference sequence, all **393 residues**, UniProt P04637. No engineered tags or additional chains.

**You**:

Where did the structure come from — AlphaFold Database, or did you run the prediction yourself?

**Dr. Margit Holló**:

It came from the public **AlphaFold Database**; I did not run the prediction myself. The coordinate file is **`p53_alphafold_model.cif`**.

**You**:

Is the model a single chain or an assembly such as a dimer or protein complex?

**Dr. Margit Holló**:

It is a **single p53 polypeptide chain**, 393 residues—not a dimer, tetramer, or protein complex. Biologically p53 can tetramerise, but this model is only one chain.

**You**:

What is the biologically functional form of the protein — does it normally work as a monomer, dimer, or with another binding partner?

**Dr. Margit Holló**:

Functionally, p53 works primarily as a **tetramer**—a four-subunit transcription factor that binds DNA. It also engages partners such as MDM2, which suppresses and regulates it, but the file you have is only one isolated p53 chain.

**You**:

What other files do you currently have — FASTA, PDB/mmCIF, confidence files, or anything else?

**Dr. Margit Holló**:

Three files:

- **`p53.fasta`** — the 393-residue reference sequence.
- **`p53_alphafold_model.cif`** — the single-chain AlphaFold coordinate model.
- **`p53_alphafold_pae.json`** — a large numerical companion file from AlphaFold; I have not used it.

No separate PDB file.

**You**:

Does the model include residue-level confidence information such as pLDDT, and do you also have a PAE/error matrix?

**Dr. Margit Holló**:

The mmCIF contains a residue-associated numerical field, and the JSON is the large grid of numbers that came with the model. I have not interpreted either; the technical part is yours, not mine.

**You**:

Does the sequence used to generate the structure exactly match the construct you use experimentally — same length, mutations, truncations, and tags?

**Dr. Margit Holló**:

The FASTA is the **393-residue wild-type human p53 reference sequence**, with no listed mutations, truncations, or tags. I have not been given a separate experimental construct specification, so I cannot claim it matches whatever construct you use at the bench.

**You**:

Which exact region or residues of the model are important for the decision you want to make?

**Dr. Margit Holló**:

The decision compares two regions:

- **N-terminal region: residues 1–93**
- **DNA-binding core: residues 94–312**

I need the mean of the residue-associated scores for each region, then a yes/no decision on whether the core is clearly higher. Separately, the proposed design target is the front-end helix around **18–28**.

**You**:

What do you want to infer from those residues specifically — for example, whether the region is folded, where a pocket is, where a binder might bind, or which residues to mutate?

**Dr. Margit Holló**:

The immediate inference is narrower: whether the **94–312 DNA-binding core** has a clearly higher mean of the residue-associated model scores than **1–93**, so we can label the core the more dependable region in the protocol. I am not asking you to locate a pocket or nominate mutations at this stage; the separate medicinal-chemistry idea is to examine the **18–28 N-terminal helix** as a possible binding target.

**You**:

What experimental decision will you make based on the structure — which mutations, molecule, construct, or experiment would change depending on the answer?

**Dr. Margit Holló**:

The practical decision is a **protocol rule**, not a mutation call. If residues **94–312** have a clearly higher regional mean than **1–93**, we will label the DNA-binding core the more dependable part for structure-guided work; if the separation is not clear, we write no such rule and avoid directing the medicinal-chemistry team on that basis. The proposed molecule against **18–28** is a separate hypothesis, not something this comparison can validate.

**You**:

Who will act on that result, and what would be the practical cost if that structural interpretation were wrong?

**Dr. Margit Holló**:

The medicinal-chemistry collaborator and the colleagues applying our shared p53 structure protocol will act on it. If wrong, they could spend limited synthesis and assay time treating the wrong region as a sound design basis—particularly costly if we direct them toward the **18–28** helix and obtain misleading binders or no useful molecule at all.

**You**:

What makes you confident that this part of the model is correct? What are you seeing in the structure that reassures you?

**Dr. Margit Holló**:

The central DNA-binding region appears compact and beautifully folded in the picture, while the N-terminus contains a clean helix around **18–28**. That is what caught my eye; biologically, the core is the domain that contacts DNA and carries the classic cancer hotspots. Which region are you asking me to justify specifically—the core or the front-end helix?

**You**:

Can you justify both regions please

**Dr. Margit Holló**:

The **94–312 core** looks compact and coherently folded, which fits its known role as p53’s DNA-contacting domain and the location of the major cancer mutations. The **18–28 segment** appears as a particularly neat, continuous helix at the front of the chain; it contains the transactivation residues that engage MDM2, so it is biologically interesting as a possible design handle.

That is visual and biological justification, not the regional numerical comparison you need. You must calculate the two means from the residue-associated values in the mmCIF before writing the protocol rule.

**You**:

For the exact residues you want to rely on, is the confidence equally strong there, or is your confidence mainly based on the overall appearance of the model?

**Dr. Margit Holló**:

I have not established that for the exact residues. My judgement so far is based mainly on the model’s appearance: the core looks compact, and **18–28** forms a clean helix. Whether the numerical values are equally strong across those regions is precisely what you must test from the mmCIF.

**You**:

Is the region you care about expected to be structured on its own, or could it become ordered only when it binds another molecule or protein?

**Dr. Margit Holló**:

Honestly, that end of p53 is pretty floppy in the tube until it latches onto MDM2, although the model shows such a clear helix that I assumed it was fine. The **18–28** segment is the MDM2-contacting transactivation motif; that distinction matters greatly before treating it as a fixed drug target.

**You**:

If multiple chains are involved, what makes you confident about how the chains sit relative to each other, rather than just that each chain folds well individually?

**Dr. Margit Holló**:

There are no multiple chains in this model, so there is no inter-chain arrangement to assess. The file is one isolated 393-residue p53 chain; its biological tetramerisation is not represented.

**You**:

Do you have any experimental evidence that the chains interact or assemble in that way?

**Dr. Margit Holló**:

For the tetramer, yes: p53 tetramerisation is established biologically through its C-terminal oligomerisation domain. But this file contains no assembled tetramer, and I have no experimental evidence from this model for any chain–chain arrangement.

**You**:

Do you have any experimental evidence that the chains interact or assemble in that way?

**Dr. Margit Holló**:

Yes, for **p53 tetramerisation** there is extensive experimental evidence involving its C-terminal oligomerisation domain. But this structure file contains only one isolated chain, so it provides no evidence for how four chains assemble—or for a p53–MDM2 complex.

**You**:

Could any residues that look surface-exposed in this model actually become buried when the biologically relevant assembly forms?

**Dr. Margit Holló**:

Yes. Residues exposed on this isolated chain could become buried at the **p53 tetramer interface**, especially near the C-terminal oligomerisation region. This model cannot tell us which surfaces are altered on assembly because it contains no tetramer; the **18–28** motif is instead an N-terminal partner-binding site, chiefly relevant to MDM2.

**You**:

Is the following statement accurate: “Our primary analysis is a residue-level comparison of the AlphaFold confidence scores for p53 residues 1–93 and 94–312. It is not a validation of the 18–28 binding hypothesis, not an analysis of tetramer assembly, and not a claim that the core is biologically more important. Any conclusion about ‘clearly higher’ must state the numerical difference and the decision criterion used.” If not, please correct my understanding before proceeding.

**Dr. Margit Holló**:

Yes, that is accurate. I would replace **“AlphaFold confidence scores”** with **“residue-associated scores recorded in the mmCIF”**; the analysis is strictly the comparison of means for **1–93** and **94–312**, and any “clearly higher” call must state the numerical difference and a predefined criterion. It does not validate **18–28**, tetramer assembly, or biological importance.

**You**:

What would be a threshold/outcome that will confirm that you trust the results.

**Dr. Margit Holló**:

I cannot choose that technical threshold for you. State it **before** calculation—for example, a minimum absolute difference or ratio between the two regional means—and report both means, their difference, and whether the rule is met. Without the actual residue-associated values from the mmCIF, I cannot say whether the outcome passes it.

**You**:

Do you expect any difficulty with this specific data considering its biological function and structure?

**Dr. Margit Holló**:

Yes. You are comparing two biologically different parts: the **94–312 core** is a compact DNA-binding domain, whereas much of **1–93** participates in regulated partner interactions and is not necessarily a persistent standalone structure. That makes the regional means potentially quite different, but you still need to define “clearly” numerically before looking at the result. Will you use an absolute difference, a ratio, or both?

**You**:

Can you elaborate the mmCIF score field with name, scale, units or interpretation and mapping to the residues? or share data that is relevant in this regard?

**Dr. Margit Holló**:

No. I cannot identify the mmCIF field name, scale, units, or interpretation from memory, and I have not inspected its schema. I can only say that the model contains one numerical value associated with each residue; you must verify the exact field definition and residue mapping in the mmCIF before calculating the regional means. The FASTA gives the residue numbering sequence, but it does not supply those values.

**You**:

Can you elaborate me this specific protein, its function, background, importance and tricky characteristics for handling (e.g., unequal regional lengths) if any

**Dr. Margit Holló**:

p53 is a **393-residue tumour suppressor** and transcription factor, normally functioning as a tetramer. Its N-terminal region, **1–93**, contains transactivation and regulatory elements; residues **18–28** include the MDM2-contacting motif. The central region, **94–312**, is the DNA-binding core and contains the major cancer hotspots, including R175, G245, R248, R249, R273 and R282. The C-terminal portion contains the tetramerisation machinery and regulatory tail, but neither assembly nor partner binding is represented in this single-chain model.

For your calculation, the regions are unequal: **1–93 has 93 residues; 94–312 has 219**. Use the arithmetic mean of the residue-associated values within each region, not sums or a pooled average; otherwise the longer core will dominate simply because it contains more residues. The main biological complication is that the N-terminal segment engages partners and may not maintain one geometry on its own, despite the neat helix shown around 18–28. Are you asking mainly about the biology, or about how to report the unequal-region comparison?

**You**:

Can you give detailed description on both biology and how you prefer the unqeual-region comparison reported?

**Dr. Margit Holló**:

Biologically:

- **Residues 1–93** comprise the N-terminal transactivation and regulatory region. Within it, **18–28** is the MDM2-contacting transactivation motif. It can adopt a helix when bound to MDM2, but that end of p53 is not a single permanently maintained structure in isolation.
- **Residues 94–312** form the central DNA-binding domain. It is the compact domain that recognizes p53 response elements, and it contains the principal tumour-associated hotspots, including **R175, G245, R248, R249, R273 and R282**.
- The remaining C-terminal sequence contains the oligomerisation region and regulatory tail. The present model is one isolated chain, so it does not establish tetramer interfaces or partner-induced rearrangements.

For the unequal comparison, report it explicitly as two **unweighted regional arithmetic means**:

| Region | Residues | Number of residues | Mean |
|---|---:|---:|---:|
| N-terminal | 1–93 | 93 | [value] |
| DNA-binding core | 94–312 | 219 | [value] |

Then give:

- **Absolute difference:** mean(94–312) − mean(1–93)
- Optionally, the ratio: mean(94–312) / mean(1–93)
- The prespecified criterion for “clearly higher”
- A binary outcome: **criterion met: yes/no**

Do not compare sums, and do not pool all 312 residues; the core has more than twice as many residues, so either approach would be dominated by its length. Also state whether any residues are missing or unmapped before calculating. The conclusion should read, for example: “The core mean was X and the N-terminal mean was Y; the difference was Z. Under the prespecified threshold of T, the core is [clearly higher / not clearly higher].”

**You**:

Can you clearly state how you prefer the results to be reported with clear definition of the format, results, and statements that will satisfy your doubt and make the answer trustable

**Dr. Margit Holló**:

Report it in this exact form:

| Region | Residues included | Expected count | Mapped count | Mean score |
|---|---:|---:|---:|---:|
| N-terminal | 1–93 | 93 | [n] | [X] |
| DNA-binding core | 94–312 | 219 | [n] | [Y] |

Before the table, state the **exact mmCIF field name**, its scale and interpretation, and how each value was mapped to the FASTA residue number. State any missing, duplicated, or unmapped residues. Use an unweighted arithmetic mean over the residues actually included; do not use sums or a pooled mean.

Then report:

> Core mean − N-terminal mean = **Y − X = Δ**.  
> Core/N-terminal mean ratio = **Y/X**.  
> Prespecified criterion for “clearly higher”: **[criterion]**.  
> Decision: **yes/no**.

The conclusion should be limited to: “Under the prespecified criterion, residues 94–312 are / are not clearly higher than residues 1–93 in the reported model score.” Do not call it evidence that the core is biologically more important, that the **18–28** helix binds a molecule, or that the model represents the tetramer. I would regard the answer as properly documented only if the numerical field definition, residue mapping, counts, both means, difference, and decision threshold are all shown.

**You**:

As an expert of structural cancer biology. What additional analysis, data comparison and results would you prefer to have to show that extra effort is provided to for this report to ensure the results are trustable

**Dr. Margit Holló**:

For a report I would want three layers of checking.

First, verify the data itself: identify the exact mmCIF field, confirm its scale and meaning from the file documentation, map every value to the FASTA numbering, and report missing, duplicated, or unmapped residues. Recalculate the two means independently, with **n = 93** for residues 1–93 and **n = 219** for 94–312.

Second, show the distributions rather than means alone: median, minimum, maximum, and quartiles for each region, plus a residue-by-residue plot. Report the absolute difference and ratio, and apply a threshold fixed before examining the result. A long core average can conceal a weak patch, just as a short N-terminal average can conceal the **18–28** segment.

Third, compare the structural result with biology, without pretending that this validates the whole model: check the 94–312 boundary against experimentally studied p53 DNA-binding-domain structures, and examine **18–28** separately against MDM2-bound structural data. I would also report sensitivity to boundary choices, for example excluding the boundary residues or analysing **18–28** as its own segment.

The final conclusion should remain narrow: whether the reported residue-associated values are clearly higher in 94–312 under the prespecified rule. It should not be presented as proof that the N-terminal helix is a fixed standalone drug target. Will your report include the actual residue-level table, or only summary statistics?

**You**:

If you have to direct me to a specific section of the protein can you state which section you are confident and which section you have doubt?

**Dr. Margit Holló**:

For structure-guided work, I would direct you first to the **DNA-binding core, residues 94–312**. It is the compact, biologically established domain, and the model’s architecture there is coherent.

I would treat **residues 1–93**, including **18–28**, with caution as a standalone target. The front-end helix is visually clean, but that segment normally becomes ordered when it engages a partner such as MDM2; I would not let the picture alone justify a fixed small-molecule target. Do you want the report to distinguish the core recommendation from the separate 18–28 hypothesis explicitly?

**You**:

So, just to make sure I have this right: you want us to compare the residue-associated scores in the AlphaFold mmCIF for the N-terminal region, residues 1–93, with those for the DNA-binding core, residues 94–312, using the mean score for each region and a prespecified numerical criterion for what counts as “clearly higher.” The purpose is to decide whether the 94–312 core can be described as the better-supported region for structure-guided work in your protocol. This comparison should **not** be interpreted as validating the 18–28 MDM2-binding helix as a fixed drug target, proving tetramer assembly, or showing that the core is biologically more important. Is that an accurate statement of the question you want the analyst to answer?

**Dr. Margit Holló**:

Yes. That is the question I want answered: compare the two regional arithmetic means, apply the prespecified numerical criterion, and decide whether **94–312** can be labelled the better-supported region for this protocol. Keep that conclusion limited to the reported model scores; it does not validate **18–28** as a fixed drug target, establish tetramer assembly, or rank biological importance.

**You**:

What number would have to be true for "clearly higher" to be satisfied. Can you give more abitrary representation of the statement.

**Dr. Margit Holló**:

I would not choose the threshold for you; it must be agreed before calculation. An explicit **illustrative** rule would be:

> “Call 94–312 clearly higher if  
> **mean(94–312) − mean(1–93) ≥ 10 score units**  
> and the core mean is at least **10% higher** than the N-terminal mean.”

With \(X=\) mean for residues 1–93 and \(Y=\) mean for 94–312:

- Absolute condition: **\(Y-X \ge 10\)**
- Relative condition: **\(Y/X \ge 1.10\)**
- Decision: **yes only if both are true**

For example, \(X=62\), \(Y=74\): difference \(=12\), ratio \(=1.19\), so **yes** under that illustrative rule. \(X=70\), \(Y=77\): difference \(=7\), so **no**. The 10-unit and 10% values are arbitrary reporting choices, not a biological law; state them as such.
